

AMENDMENTS TO THE SPECIFICATION

Please insert the following new paragraph on page 1 between the Title and the first line:


This application is a 371 U.S. national stage application of International Application No. PCT/EP2005/000643, filed on January 24, 2005, that has priority benefit of European Patent Application No. 04002055.4, filed on January 30, 2004.

Please replace the paragraph on page 4, lines 18 to 28, with the following amended paragraph:

The salts which can be prepared by the method of the invention, such as, ~~for example,~~ (1*R*,2*S*,3*R*,4*R*)-2,3-isopropylidenedioxy-4-(methoxymethyl)-cyclopentan-1-amine ~~hydroxyl~~ hydrogen oxalate can in principle be obtained by anion exchange and reprecipitation from the corresponding hydrochlorides. However, they are not obtainable as direct hydrolysis product from the *N*-BOC compound mentioned in WO-A 00/23447, because the BOC protective group must first be eliminated with a strong acid. Moreover, reprecipitation of an HCl-acidic salt with an organic acid is not favored.

Please replace the paragraph on page 9, line 18, to page 10, line 1, with the following amended paragraph:

In a further preferred method, (1*S*,2*R*,6*S*,7*R*)-8-acetyl-4,4-dimethyl-3,5-dioxa-8-azatricyclo[5.2.1.0^{2,6}]decan-9-one is converted by reaction with a complex metal hydride into (1*R*,2*S*,3*R*,4*R*)-N-[2,3-isopropylidenedioxy-4-(hydroxymethyl)cyclopentan-1-yl]acetamide ~~(1*R*,2*S*,2*R*,4*R*)-N-[2,3-isopropylidenedioxy-4-(hydroxymethyl)cyclopentan-1-yl]acetamide~~ of the formula:



Va

Please replace the paragraph on page 15, lines 24 to 27, with the following amended paragraph:

Example 3

~~(1*R*,2*S*,3*R*,4*R*)-*N*-[2,3-Isopropylidenedioxy-4-(hydroxymethyl)-cyclopentan-yl]acetamide~~ (1*R*,2*S*,3*R*,4*R*)-*N*-[2,3-Isopropylidenedioxy-4-(hydroxymethyl)-cyclopentan-1-yl]acetamide (formula Va = formula V with R² = R³ = methyl)

Please replace the paragraph on page 16, lines 20 to 23, with the following amended paragraph:

Example 4

~~(1*R*,2*S*,3*R*,4*R*)-*N*-[2,3-Isopropylidenedioxy-4-(methoxymethyl)cyclopentan-1-yl]acetamide~~ (1*R*,2*S*,3*R*,4*R*)-*N*-[2,3-Isopropylidenedioxy-4-(methoxymethyl)cyclopentan-1-yl]acetamide (formula IVa = formula IV with R¹ = R² = R³ = methyl)